Stockscreener 앱 받기
23.00
1.41%
0.32
시간 외 거래:
21.70
-1.30
-5.65%
전일 마감가:
$22.68
열려 있는:
$22.53
하루 거래량:
3.00M
Relative Volume:
1.71
시가총액:
$2.89B
수익:
$715.22M
순이익/손실:
$-250.10M
주가수익비율:
-11.33
EPS:
-2.03
순현금흐름:
$-205.58M
1주 성능:
-3.32%
1개월 성능:
-8.55%
6개월 성능:
-19.24%
1년 성능:
-58.71%
1일 변동 폭
$21.92
$23.10
1주일 범위
$21.70
$24.88
52주 변동 폭
$21.70
$58.12
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
APLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
23.00 | 2.89B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag - TradingView
Apellis Looks To Unlock Blockbuster Potential For Empaveli, SyfovreOn A Path To Profitability - RTTNews
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Benzinga
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation - TipRanks
Applis wins FDA review to expand Empaveli label (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases - MarketScreener
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - The Manila Times
Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for Empaveli (pegcetacoplan) for C3G and Primary IC-MPGN - MarketScreener
(APLS) Investment Analysis - news.stocktradersdaily.com
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; ElevateBio trims team - Fierce Biotech
Apellis Pharma stock hits 52-week low at $23.77 amid market challenges - Investing.com Australia
Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Apellis Pharma stock hits 52-week low at $23.77 amid market challenges By Investing.com - Investing.com South Africa
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Apellis Pharmaceuticals chief development officer sells shares worth $39,279 - MSN
Interesting APLS Put And Call Options For May 16th - Nasdaq
Apellis Pharmaceuticals (APLS) Gets a Hold from Scotiabank - The Globe and Mail
Cardurion Taps Apellis Veteran Who Led 450% Team Growth for Top HR Role - StockTitan
University Retina Participate in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy - Business Wire
Apellis Pharmaceuticals CFO Timothy Sullivan sells $51,827 in stock - MSN
(APLS) Long Term Investment Analysis - news.stocktradersdaily.com
Apellis Pharmaceuticals executive sells shares valued at $4,542 By Investing.com - Investing.com Australia
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre - Benzinga
Apellis Pharmaceuticals Beats Investor Suit Over Eye Drug Risks - Bloomberg Law News
Apellis Pharmaceuticals executive sells shares valued at $4,542 - Investing.com India
Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt - Simply Wall St
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Bank of New York Mellon Corp - Defense World
Victory Capital Management Inc. Purchases 150,363 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Will Apellis Pharma's Empaveli Prove VALIANT In Battling Rare Kidney Diseases? - RTTNews
Learn to Evaluate (APLS) using the Charts - news.stocktradersdaily.com
Apellis Pharmaceuticals general counsel sells shares for $139,789 By Investing.com - Investing.com South Africa
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Insider Sells Thousands of Apellis Pharmaceuticals Shares! - TipRanks
Apellis Pharmaceuticals general counsel sells shares for $139,789 - Investing.com India
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics - MSN
HC Wainwright Issues Pessimistic Forecast for APLS Earnings - Defense World
Wedbush Lifts Earnings Estimates for Apellis Pharmaceuticals - Defense World
Wedbush Issues Optimistic Outlook for APLS Earnings - Defense World
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues - MSN
Apellis Pharmaceuticals: A Mixed Bag (NASDAQ:APLS) - Seeking Alpha
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga India
UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating - Marketscreener.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript - MSN
JPMorgan Chase & Co. Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts - MSN
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):